← All trials
NCT06027307
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2023
- Primary completion
- Apr 30, 2026
- Completion date
- Oct 31, 2027
- First posted
- Sep 7, 2023
- Last posted
- Oct 26, 2023
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UlsanLead sponsor
- Daewoong Pharmaceutical Co. LTD.Collaborator
- University of UlsanOverall official - principal investigator
- University of UlsanReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.